Steven Lichtman
Stock Analyst at Oppenheimer
(2.95)
# 1,609
Out of 4,996 analysts
71
Total ratings
41.18%
Success rate
12.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $12.00 | +83.33% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $318.00 | +14.78% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $98.18 | +27.32% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $67.10 | +52.01% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $98.24 | +37.42% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.53 | +117.00% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $73.92 | +48.81% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $94.22 | -0.23% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $9.03 | +619.82% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $14.66 | -24.97% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $10.68 | +12.36% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $80.20 | +8.48% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.70 | +397.02% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $369.02 | -21.96% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $79.92 | +31.38% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $26.80 | +459.70% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $67.55 | +25.83% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $12.00
Upside: +83.33%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $318.00
Upside: +14.78%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $98.18
Upside: +27.32%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $67.10
Upside: +52.01%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $98.24
Upside: +37.42%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.53
Upside: +117.00%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $73.92
Upside: +48.81%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $94.22
Upside: -0.23%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $9.03
Upside: +619.82%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $14.66
Upside: -24.97%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $10.68
Upside: +12.36%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $80.20
Upside: +8.48%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.70
Upside: +397.02%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $369.02
Upside: -21.96%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $79.92
Upside: +31.38%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $26.80
Upside: +459.70%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $67.55
Upside: +25.83%